REG - Beximco Pharma. - Notification of Preliminary Results and AGM

Beximco PharmaceuticalsAnnouncement

20/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231020:nRST7172Qa&default-theme=true

RNS Number : 7172Q  Beximco Pharmaceuticals Ltd  20 October 2023

 

20 October 2023

 

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation 596/2014 which is part of English Law
by virtue of the European (Withdrawal) Act 2018, as amended. On publication of
this announcement via a regulatory information service, this information is
considered to be in the public domain.

 

 

BEXIMCO PHARMACEUTICALS LIMITED

 

Notification of Preliminary Results and Annual General Meeting

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM
Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical ingredients, today
announces information for shareholders of the Company that the Board of
Directors decided at their meeting held on 19 October 2023. Please see further
detail as follows:

 

 

 1.  To recommend the approval of the Financial Statements for the year ended 30  The Audited Financial Statements for the year ended 30 June 2023 have been
     June 2023                                                                    approved. The full accounts are expected to be announced by 01 November 2023
 2.  Date & Time of 47(th) Annual General Meeting ("AGM") of the Company for      28 December 2023 at 10.30 A.M.
     the year ended 30 June, 2023
 3.  Venue of AGM                                                                 Virtual Platform

 4.  Proposed Dividend for the year ended 30 June 2023                            35% Cash Dividend (i.e. Tk 3.50 per Share)
 5.  Record date                                                                  13 November 2023

 

 

Comparative Financial Disclosures:

 

Beximco Pharmaceuticals Limited (Stand-alone)

 

 

 Particulars                                 Year ended           Year ended

                                             30 June 2023         30 June 2022
 Net Profit after Tax                        Tk. 4,588,008,908    Tk.  5,161,343,643
 Earnings Per Share (EPS)                    Tk. 10.28            Tk. 11.57
 Net Asset Value (NAV)                       Tk. 43,341,239,142   Tk. 40,315,738,301
 Net Asset Value per share (NAVPS)           Tk.97.15             Tk. 90.37
 Net Operating Cash Flow Per Share (NOCFPS)  Tk. 12.96            Tk. 11.27

 

 

Beximco Pharmaceuticals Limited and its Subsidiaries (Consolidated)

 

 Particulars                                 Year ended          Year ended

                                             30 June 2023        30 June 2022
 Net Profit after Tax                        Tk. 4,524,468,490   Tk. 4,998,628,197
 Earnings Per Share (EPS)                    Tk. 10.34           Tk. 11.48
 Net Asset Value (NAV)                       Tk. 43,680,703,738  Tk. 40,600,497,817
 Net Asset Value per share (NAVPS)           Tk. 97.91           Tk. 91.01
 Net Operating Cash Flow Per Share (NOCFPS)  Tk. 13.64           Tk. 11.69

 

 

 

For further information please visit www.beximcopharma.com
(http://www.beximcopharma.com) or enquire to:

 

Beximco Pharma

 

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, Ext.20080

 

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext.20111

 

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext.20030

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0) 20 3368 3551 / 3555

 

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in
Bangladesh. Since its inception in 1976, the Company remains committed to
health and wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics encompasses
diverse delivery systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers, sterile
ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser
solutions, oral soluble films etc. The Company also undertakes contract
manufacturing for multinational and leading global generic pharmaceutical
companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by
global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more than 50
countries. More than 5,500 employees are driving the company towards achieving
its aspiration to be among the most admired companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORGPGAWUUPWGCB